镓-68 PSMA-11 PET用于甲状腺癌成像的可行性研究
这项前瞻性试点研究纳入有病理证实甲状腺癌且近12个月内FDG PET和/或131I显像异常摄取的成人患者,行[68Ga]Ga-PSMA-11 PET/MRI并与既往FDG PET比较。11例可分析患者中,43个病灶的FDG阳性检出率为95.3%,PSMA阳性检出率为65.1%,提示PSMA PET对甲状腺癌病灶的检出率低于FDG PET。
要点
- 甲状腺癌病灶PSMA阳性检出率65.1%,低于FDG的95.3%
- 3/11例患者PSMA摄取高于FDG,8/11例FDG摄取更高
- 甲状腺癌亚型不能单独预测PSMA摄取,患者间及患者内摄取不均
核心结论
- [68Ga]Ga-PSMA-11 PET对甲状腺癌病灶的检出率低于2-[18F]FDG PET。
- 甲状腺癌亚型本身可能不足以预测PSMA摄取,示踪剂摄取在患者间甚至患者内存在差异。
研究设计与样本
- 前瞻性试点研究,纳入有病理证实甲状腺癌病史、且入组前12个月内2-[18F]FDG PET和/或131I闪烁显像显示异常放射性摄取的成人患者。
- 患者接受[68Ga]Ga-PSMA-11 PET/MRI,并与既往合格的2-[18F]FDG PET CT/MRI就病灶位置和相对强度进行比较。
- 共12例患者接受[68Ga]Ga-PSMA-11 PET/MRI,其中1例因PSMA PET前接受减瘤手术被排除分析,最终11例纳入分析。
主要发现
- 11例可分析患者中,7/11为分化型疾病(3例乳头状、2例滤泡状、2例Hurthle细胞),4/11为去分化疾病(2例低分化乳头状、2例未分化)。
- 43个病灶中,41个为2-[18F]FDG视觉阳性(摄取高于背景,检出率95.3%),28个为PSMA阳性(摄取高于背景,检出率65.1%)。
- 摄取在患者间存在异质性,部分病例在患者内也存在异质性。
- 3/11例患者(1例低分化乳头状、2例滤泡状)PSMA摄取高于FDG摄取;其余8例患者FDG摄取高于PSMA。
- 参照前列腺癌文献中PSMA放射性配体治疗(RLT)的一条入选指南,8/11例可考虑为未来可能适合PSMA RLT,但这无法根据甲状腺癌亚型预测。
关键数值与推荐
- 43个病灶中41个2-[18F]FDG视觉阳性,检出率95.3%。
- 43个病灶中28个PSMA视觉阳性,检出率65.1%。
- 参照前列腺癌文献中PSMA RLT的一条入选指南,8/11例可考虑为可能适合未来PSMA RLT。
临床怎么用
- 在甲状腺癌病灶显像中,[68Ga]Ga-PSMA-11 PET检出率低于2-[18F]FDG PET,不宜直接替代FDG PET。
- 评估未来PSMA RLT可能性时可参考前列腺癌文献中的入选指南,但不能仅凭甲状腺癌亚型预测PSMA摄取。
- 由于患者间及患者内摄取存在异质性,PSMA摄取情况需个体化评估。
局限性
- 本研究为前瞻性试点研究,最终仅11例患者纳入分析,样本量小。
- PSMA PET/MRI仅与既往合格的2-[18F]FDG PET CT/MRI进行比较。
- PSMA RLT适用性评估借用了前列腺癌文献中的一条入选指南,并非甲状腺癌专用标准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prostate-specific membrane antigen (PSMA) is expressed in the microvasculature of thyroid cancer. This suggests the potential use of PSMA as a diagnostic agent in patients with aggressive forms of thyroid cancer. The purpose of the current study was to determine the feasibility and utility of [68Ga]Ga-PSMA-11 PET/MRI in thyroid cancer patients. METHODS: Eligible patients for this prospective pilot study were adults with a history of pathology-proven thyroid cancer who had abnormal radiotracer uptake on an 2-[18F]FDG PET and/or 131I scintigraphy performed in the 12 months prior to study enrollment. Patients underwent a [68Ga]Ga-PSMA-11 PET/MRI, and comparison was made to the prior qualifying 2-[18F]FDG PET CT/MRI for lesion location and relative intensity. RESULTS: Twelve patients underwent [68Ga]Ga-PSMA-11 PET/MRI, one of which was excluded from analysis due to debulking surgery prior to the PSMA PET. Of the remaining patients, 7/11 had differentiated disease (3 papillary, 2 follicular, 2 Hurthle cell) and 4/11 had dedifferentiated disease (2 poorly differentiated papillary, 2 anaplastic). Out of 43 lesions, 41 were visually 2-[18F]FDG positive (uptake greater than background, detection rate 95.3%) and 28 were PSMA positive (uptake greater than background, detection rate 65.1%). Uptake was heterogeneous between patients, and in some cases within patients. 3/11 patients (1 poorly differentiated papillary, 2 follicular) had PSMA uptake which was greater than FDG uptake. For the remaining 8 patients, 2-[18F]FDG uptake was greater than PSMA. Using one eligibility guideline in the prostate cancer literature for PSMA radioligand therapy (RLT), 8/11 could be considered eligible for possible future PSMA RLT. This was not predictable based on thyroid cancer subtype. CONCLUSIONS: [68Ga]Ga-PSMA-11 PET demonstrated lower detection rate when compared to 2-[18F]FDG PET for thyroid cancer lesion visualization. Thyroid cancer subtype alone may not be sufficient to predict PSMA uptake, and radiotracer uptake may vary between patients and even within patients.
引用
- Lawhn-Heath C, Yom SS, Liu C, et al. Gallium-68 prostate-specific membrane antigen ([68Ga]Ga-PSMA-11) PET for imaging of thyroid cancer: a feasibility study. EJNMMI Res. 2020. PMID: 33090273. doi:10.1186/s13550-020-00720-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。